Genmab CEO hopes arbitration uncertainties will ease off soon

So far, Johnson & Johnson has refused Genmab around half a billion kroner (USD 76m) in a royalty dispute. Investors might be scared off until the verdict is in, says CEO Jan van de Winkel.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

Genmab is hoping that 2022 will bring an end to the arbitration dispute with the company’s partner Johnson & Johnson concerning the rights to the huge revenue inflows from cancer drug Darzalex.

The two firms fell into disagreement in 2020, resulting in Johnson & Johnson withholding royalty payments in 2020–2021 in the ballpark of half a billion kroner (USD 76m), Genmab has assessed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs